Document Detail


The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
MedLine Citation:
PMID:  11893129     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Warfarin sodium (warfarin) is commonly prescribed in surgical practice. Warfarin use is complicated by an unpredictable dose response that may be due in part to genetically determined differences in metabolic capacity. To better understand the interaction between genotype and response to warfarin therapy, we determined the frequency and functional effects of polymorphisms of the predominant cytochrome P450 subfamily responsible for warfarin metabolism (eg, CYP2C9) in an ethnically defined U.S. patient population. DESIGN: Patients requiring chronic anticoagulation with warfarin sodium (warfarin) were recruited over an 11-month period (June 1999 through May 2000) from the inpatient and outpatient divisions of a tertiary care medical center in this prospective observational study. Clinical and demographic information was collected and CYP2C9 genotype was determined. RESULTS: One hundred fifty-three patients receiving warfarin therapy for at least four weeks and comprising two ethnic groups [33 African Americans (22%) and 120 Caucasians (78%)] were genotyped. The mean weekly warfarin dose (+/-SEM) for all patients [36.9 (+/- 1.5) mg] was not influenced by gender [85 males (56%), 68 females (44%)] or ethnicity (p>0.05 for both), but was significantly affected by age (p = 0.006 for weight adjusted warfarin dose). The frequencies of CYP polymorphisms were as follows: 2C9*2 (24/153) 15.7%, 2C9*3 (23/153) 15.0%. There were no gender differences in polymorphism frequency (CYP2C9*2 frequency = (13/ 85) 15.3% in males, (12/68) 17.6% in females, p=0.74; CYP2C9*3 frequency = (15/85) 17.6% in males and (8/68) 11.8% in females, p = 0.38). CYP polymorphisms were much less common in African Americans than Caucasians [(5/33) 15.2% versus (47/120) 39.2%, respectively p = 0.05)]. Patients with CYP polymorphisms (2C9*2, 2C9*3) had significantly lower warfarin doses compared to patients with wild-type genotypes [30.6 (+/- 2.5) mg versus 40.1 (+/- 1.7) mg, p = 0.0021] . Stepwise backward regression analysis suggested a moderate ability to predict warfarin dose based on CYP genotype (r2 = 0.26), p < 0.01). CONCLUSIONS: CYP2C9 polymorphisms are common, associated with significant reductions in warfarin dose, and partly account for interpatient variability in warfarin sensitivity. As interactions between genetic factors and other variables that influence warfarin effect are more completely understood, CYP analysis may prove a useful adjunct for increasing the safety and efficacy of this agent.
Authors:
Arash Rafii Tabrizi; Barbara A Zehnbauer; Ingrid B Borecki; Sean D McGrath; Timothy G Buchman; Bradley D Freeman
Related Documents :
3757529 - Verapamil infusions in the treatment of atrial tachyarrhythmias.
7732989 - Chaotic atrial rhythm in children.
17224069 - Use of patient flow analysis to improve patient visit efficiency by decreasing wait tim...
2971749 - Diagnostic importance of fibrillatory wave amplitude: a clue to echocardiographic left ...
16222889 - Endothelial dysfunction, distensibility and intima-media thickness and aetiology of str...
11893129 - The frequency and effects of cytochrome p450 (cyp) 2c9 polymorphisms in patients receiv...
8149019 - Hypercoagulable states as an evolving risk for spontaneous venous and arterial thrombosis.
6083619 - Early phlebographic results after iliofemoral venous thrombectomy.
3081699 - Monocyte bone degradation: in vitro analysis of monocyte activity in patients with juve...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the American College of Surgeons     Volume:  194     ISSN:  1072-7515     ISO Abbreviation:  J. Am. Coll. Surg.     Publication Date:  2002 Mar 
Date Detail:
Created Date:  2002-03-14     Completed Date:  2002-03-29     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9431305     Medline TA:  J Am Coll Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  267-73     Citation Subset:  AIM; IM    
Affiliation:
Department of Surgery, Washington University School of Medicine, St Louis, MO, 63110, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
African Americans
Anticoagulants / therapeutic use*
Aryl Hydrocarbon Hydroxylases*
Cytochrome P-450 Enzyme System / genetics*
European Continental Ancestry Group
Female
Genotype
Humans
Male
Middle Aged
Polymorphism, Genetic*
Prospective Studies
Regression Analysis
Steroid 16-alpha-Hydroxylase*
Steroid Hydroxylases / genetics*
Warfarin / therapeutic use*
Grant Support
ID/Acronym/Agency:
GM00691/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/Anticoagulants; 81-81-2/Warfarin; 9035-51-2/Cytochrome P-450 Enzyme System; EC 1.14.-/Steroid Hydroxylases; EC 1.14.14.1/Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1/CYP2C9 protein, human; EC 1.14.14.1/Steroid 16-alpha-Hydroxylase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identifying patient preoperative risk factors and postoperative adverse events in administrative dat...
Next Document:  Thyroglossal duct: a review of 55 cases.